Ensartinib
Stage I
Shanghai Pulmonary Hospital, Shanghai, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Stage I cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Jair Bar, M.D., Ph.D. | Phase 1 | CC |
Same molecule, other indications
Ensartinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →